Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Lyra Therapeutics Inc
LYRACurrent price
0.27 USD
-0.0026 USD (-0.94%)
Last closed
0.28 USD
Company
lyratherapeutics.com
ISIN
US55234L1052
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
18 327 876 USD
Yield for 12 month
-94.30 %
1Y
3Y
5Y
10Y
15Y
LYRA
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.25 USDP/E ratio
–Dividend Yield
–Current Year
+1 558 000 USD
Last Year
+1 363 000 USD
Current Quarter
+598 000 USD
Last Quarter
+532 000 USD
Current Year
+1 280 000 USD
Last Year
+296 000 USD
Current Quarter
+453 000 USD
Last Quarter
+396 000 USD
Key Figures LYRA
1 year
3 years
5 years
10 years
EBITDA
-74 335 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-42.36 %
PEG Ratio
–
Return On Equity TTM
-156.52 %
Wall Street Target Price
1.25 USD
Revenue TTM
1 820 000 USD
Book Value
0.47 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
30.6 %
Dividend Yield
–
Gross Profit TTM
-34 234 000 USD
Earnings per share
-1.56 USD
Diluted Eps TTM
-1.56 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics LYRA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LYRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation LYRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
153.7687
Price Sales TTM
10.0703
Enterprise Value EBITDA
0.6593
Price Book MRQ
0.5917
Financials LYRA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators LYRA
For 52 weeks
0.25 USD
6.79 USD
50 Day MA
0.3 USD
Shares Short Prior Month
4 151 198
200 Day MA
2.9 USD
Short Ratio
2.8
Shares Short
2 962 989
Short Percent
5.65 %
BeatStart